INTRODUCTION KELETAL
MUSCLE IS A PRIMARY TARGET for the delivery of systemic therapeutic agents through gene therapy (Blau and Springer, 1995b) because of its capacity to express foreign DNA either injected directly as plasmid DNA (Wolff et al., 1990) , or injected as ex vivo-modified myoblasts (Barr and Leiden, 1991 ; Dhawan et al., 1991) . In both instances, the DNA is incorporated into the host's postmitotic myofibers and results in the long-term expression and delivery of soluble, bioactive compounds to the circulation. Myoblast gene therapy has successfully delivered factors such as growth hormone (Barr and Leiden, 1991; Dhawan et al., 1991) , factor IX (Yao and Kurachi, 1992) , and erythropoietin (Hamamori et al., 1994 (Hamamori et al., , 1995 , whereas direct intramuscular injection of plasmid DNA containing the sequence for kallikrein (Xiong et al., 1995) or kallikrein-binding protein (Ma et al., 1995) leads to the systemic delivery of these blood pressure-regulating molecules.
Several problems currently exist with these gene therapy protocols. First, the in vivo incorporation of injected plasmid DNA and myoblasts into host myofibers is variable and inefficient (Acsadi et al., 1991; Huard et al., 1995) , making delivery of a predetermined level of a bioactive compound difficult. Second, the foreign DNA can remain dormant for extended periods in vivo (Yao et al., 1994) , or can migrate through the vascular sys-tem to other sites (Neumeyer et al., 1992) . Subsequent surgical removal of the foreign DNA-containing tissue, if necessary, would thus be difficult.
Tissue engineering is a new discipline for the in vitro construction of varied tissues such as pancreatic islets, liver, skin, cartilage, bone, muscle, and blood vessels (Langer and Vacanti, 1993) . Although the primary goal of tissue engineering is to replace the function of a deficient organ, engineered tissues may also serve as a vehicle for gene therapy. Skeletal muscle myoblasts can be tissue engineered in vitro into organ-like structures (organoids) containing parallel, postmitotic myofibers connected to tendon-like structures and organized into fascicles, the functional unit of muscle (Vandenburgh et al., 1991) . et al., 1996) .
tached from the silicone rubber mold, and was held at its ends by the Velco or stainless steel screening. The gel contracted to form a cylindrical structure approximately 2.5 mm in diameter by 18 mm in length. After 4-5 days in fusion medium, the organoids were switched to a maintenance medium (DMEM with high glucose, 10% horse serum, 5% FCS, and 100 units/ml penicillin), and treated with 1 izg/ml cytosine arabinoside (araC)
for 4--6 days to remove nonfused proliferating cells. The organoids were maintained in this maintenance medium for 5-12 days before implantation. A 20-to 30mm incision was made along the mid-line, the skin was reflected, organoids were inserted under the skin flap, and the wound sutured closed. Implantation of the organoids is a rapid procedure (<10 min) and up to four implants can be inserted into each animal. The mice were injected with 60 mg/kg cyclosporine A at least I hr before surgery and daily thereafter to suppress antibody production to rhGH (Behara et al., 1992) .
MATERIALS AND METHODS
Levels of rhGH were greatest in animals receiving multiple im- Delivery of rhGH from tissue engineered muscle organoids is a rapidly reversible procedure. A. A 40-day subcutaneous implanted organoid retains its morphologically distinct structure. The silicone rubber mold that holds the organoid under tension in vivo is removed for the photograph.
The black Velcro end pieces to which the organoid is attached are indicated by arrows. The reddish color of the implant indicates that it is well vascularized.
B. Six animals are implanted with rhGH-secreting muscle organoids and on days 6-7 post-implant, implants are surgically removed (at R on graph) from 3 animals. C on the graph is an animal implanted with a control non-rhGH-secreting C2C12 organoid. Of the 32 survivors, 27 produced constant physiological serum levels of rhGH (al-Hendy et al., 1995) , ranging from 0.5 to 3.5 ng/ml, from 24 hr to 10-14 days post-implantation (Fig. 1A) . These rhGH levels are similar to those obtained with either di- 
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Days In Vivo Weekly rhGH serum levels for animals implanted subcutaneously under tension with one organoid/animal. Values are means _ SE for n = 25 (week 1) to n = 5 (week 12). There are no significant differences (p > 0.5) between week 1 and week 12 values (paired t-test, n = 5). C. Organoids implanted under no tension (day 0) produce similar levels of rhGH to organoids implanted under tension for 9 days in vivo, but by 60 days the secretion levels from no-tension implants are decreased compared to organoids implanted under tension. Bars are means ±SE. A second experiment of this type gave similar results.
• ENGINEERED MYOFIBERS
FOR GENE THERAPY 2199 a mean half-life of 10 min for rhGH in vivo (Strobl and Thomas, 1994) , it can be calculated that 28-30% of the rhGH produced by the organoids in vitro appears in the blood within 24 hr of implantation.
These results imply that subcutaneous organoid implantation is an efficient site for rhGH delivery. Organoids continue to produce consistent levels of rhGH for 10--I 2 weeks in vivo, without any significant change from the secretion levels seen at ! week (Fig. IB) .
Week-to-week variations in rhGH levels were noted in the same animals (approximately two-to three-fold, e.g., closed circle-solid line animal in Plate 2B) from 2 weeks to 12 weeks post implantation and may result from host regulation of rhGH transcription, translation, and/or secretion from the muscle fibers (Crystal, 1995) . The consistent release of rhGH from the organoids is in marked contrast to rhGH secretion resulting from intramuscularly injected C2MIXAB myoblasts, where a 10-to 15-fold variation in serum rhGH levels occurs during the 12 weeks following injection (Dhawan et al., 1991) . The delivery of rhGH from organized postmitotic myofibers also appears to have advantages over its delivery from collagen-embedded proliferating, genetically modified fibroblasts, where reduced secretion with time results in a 95% loss in serum levels by 42 days in vivo (Chen et al., 1995) .
Maintaining the implanted organoids under tension is important for optimal long-term secretion of rhGH. Implantation of organoids under no tension results in a 77% reduction (p < 0.05) in serum rhGH levels after 60 days in vivo compared to organoids implanted under tension (Fig. 1C ). Loss of tension on organoid myofibers in vitro leads to significant myofiber atrophy, indicated by a 35% loss in organoid cellular proteins after 6 days of tension release (n = 4, p < 0.01). It has been reported by others that injection of myoblasts and disorganized myofibers provides a better bioactive compound delivery system than injection of myoblasts only (Jiao et al., 1993) , possibly because of the greater protein synthesis capacity of postmitotic muscle fibers compared to myoblasts. Prevention of myofiber atrophy in organoid structures by maintaining them under tension following implantation as done in the present study would further enhance the myofibers' large protein synthetic capability.
The systemic delivery of rhGH from the skeletal muscle organoids is a reversible procedure. For certain cell-based delivery techniques such as for bone repair (Fang et al., 1996) et al., 1991) . Their use as a delivery system of bioactive molecules through genetic engineering has additional potential advantages over other forms of muscle gene therapy. Recent evidence indicates that direct gene transfer by plasmid DNA injection in vivo may be even more difficult in primates than rodents because the thicker extracellular matrix around in vivo primate myofibers may inhibit DNA uptake by the muscle cells (Jiao et al., 1992) . This problem would not exist for the organoid delivery technique because insertion of the foreign DNA occurs before connective tissue formation. Another advantage of the organoid technique is that only postmitotic cells containing foreign DNA are implanted, reducing potential problems associated with proliferating cell transformation and tumor formation (Vile and Russell, 1995) . Finally, techniques are well established for the successful removal and reimplantation of human skeletal muscle organs during reconstructive surgery and may be useful for long-term human muscle organoid implantation into an intramuscular site where it could possibly become innervated.
In summary, this preliminary report describes a new method for the delivery of physiological levels of a bioactive compound from organized postmitotic myofibers that combines gene therapy and tissue engineering techniques.
Although still facing major hurdles before clinically effective therapies are possible (Crystal, 1995) , skeletal muscle delivery systems for gene therapy look promising for future development.
